Medline Inc.

424B4 priced

Medline Inc. is offering 75,000,000 Class A common shares via a prospectus supplement (424B4), with underwriters having an option to purchase an additional 11,250,000 shares. The offering includes exchanges of Common Units for shares by selling stockholders, who will receive proceeds. The company itself does not benefit financially. The filing outlines underwriting terms, including a public offering price of $41.00 per share and underwriting discounts of $0.492 per share.

EFFECT effective

Medline Inc. has received SEC approval for its IPO, with the registration statement effective as of March 4, 2026. The offering involves 75 million Class A common shares, with underwriters having an option to purchase additional shares. The company will not receive proceeds from the sale, which are managed by selling stockholders. The filing includes details on underwriting terms, exchange agreements for Common Units, and organizational structure.

S-1 filed

Medline Inc. is conducting an initial public offering (IPO) of 75,000,000 shares of Class A common stock. The offering is led by underwriters including Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities, and J.P. Morgan. The company, previously a private entity, has restructured its ownership through the exchange of units for shares, with proceeds from the sale going to selling stockholders rather than the company itself. The filing includes details on organizational structure, risk factors, and underwriting terms.

DRS filed

Medline Inc. has filed a DRS registration statement for the offering of Class A common stock, following its December 2025 IPO. The current filing outlines the sale of shares by selling stockholders, with no proceeds to Medline Inc. It references prior reclassifications of equity units, exchange agreements, and organizational restructuring post-IPO. The filing emphasizes risks related to market competition, regulatory compliance, and operational dependencies.

424B4 priced

Medline Inc. is conducting its initial public offering (IPO) of 216,034,482 shares of Class A common stock at $29.00 per share, totaling $6.26 billion. The offering includes proceeds to be used for acquiring Common Units from Medline Holdings, LP to repay debt, fund corporate purposes, and redeem pre-IPO equity interests. The company will list on Nasdaq under 'MDLN' with dual-class voting structure. The offering involves complex organizational transactions, including reclassifications of unit holdings and interactions with cornerstone investors and underwriters.

8-A12B effective

Medline Inc. is registering its Class A common stock under Section 12(b) of the Securities Exchange Act of 1934, transitioning from its initial S-1 registration statement (File No. 333-291112) to a formal listing on Nasdaq. The filing incorporates by reference the prospectus from the S-1, which outlines the capital structure and securities details. No additional securities are being registered under Section 12(g).

EFFECT effective

Medline Inc. has received SEC approval for its IPO registration statement (Form S-1), confirming the effectiveness of its initial public offering. The company plans to issue 179 million Class A shares at an expected price range of $26.00-$30.00 per share. Proceeds will be used to acquire Common Units from Medline Holdings, LP for debt repayment, corporate purposes, and offering expenses. The offering includes underwriter options for additional shares and participation from cornerstone investors.

S-1/A amended

Medline Inc. is conducting an initial public offering (IPO) of 179,000,000 shares of Class A common stock, with an expected price range of $26.00 to $30.00 per share. The offering aims to raise capital to acquire Common Units from Medline Holdings, LP, which will be used for debt repayment, corporate purposes, and covering offering expenses. The company plans to list on Nasdaq under the symbol 'MDLN'. The filing includes details on underwriters, cornerstone investors, and the use of proceeds, with adjustments to share quantities and investor commitments compared to the previous filing.

S-1/A amended

Medline Inc. is conducting an initial public offering (IPO) of its Class A common stock, with the proceeds intended to acquire Common Units from Medline Holdings, LP for debt repayment, corporate purposes, and offering expenses. The company will maintain two classes of common stock post-offering, each with equal voting rights. The filing includes detailed organizational structure changes, underwriting arrangements, and use of proceeds, with an expected offering price range and Nasdaq listing.

S-1 filed

Medline Inc. is conducting an initial public offering (IPO) of Class A common stock, with shares to be listed on Nasdaq under the symbol 'MDLN.' The offering aims to raise capital through the sale of shares, with proceeds used to acquire Common Units from Medline Holdings, LP, which will be utilized for general corporate purposes, including debt repayment. The company will have two classes of common stock post-offering, with Class A and Class B shares each entitling holders to one vote. The offering involves complex organizational restructuring, including the conversion of existing equity interests into shares.

DRS/A amended

Medline Inc. is conducting an initial public offering (IPO) of its Class A common stock, with shares expected to be listed on the Nasdaq Global Select Market under the symbol 'MDLN.' The offering aims to raise capital through the issuance of shares, with proceeds used to acquire Common Units from Medline Holdings, LP, and to fund general corporate purposes. The company will maintain two classes of common stock post-offering, with Class A and Class B shares each entitling holders to one vote. The filing includes details on organizational structure, use of proceeds, and equity conversions tied to the IPO.

DRS/A amended

Medline Inc. is conducting its initial public offering (IPO) of Class A common stock, with shares to be listed on Nasdaq under the symbol 'MDLN.' The offering aims to raise capital through the sale of shares, with proceeds used to acquire Common Units from Medline Holdings LP and for general corporate purposes. The company will maintain two classes of common stock post-offering, with Class A and Class B shares each entitling holders to one vote. The offering includes underwriter options to purchase additional shares and involves organizational restructuring through unit conversions.

DRS/A amended

Medline Inc. is conducting an initial public offering (IPO) of Class A common stock, with plans to list on Nasdaq under the symbol 'MDLN.' The offering involves the sale of shares to acquire newly issued units from Medline Holdings, LP, which will be used for general corporate purposes, including debt repayment. The company will maintain two classes of common stock, Class A and Class B, each with equal voting rights. The filing highlights organizational restructuring, including the reclassification of units and transactions with pre-IPO owners.

DRS/A amended

Medline Inc. is conducting an initial public offering (IPO) of Class A common stock, with plans to list on Nasdaq under the symbol 'MDLN.' The company will have two classes of common stock post-offering, with proceeds from the IPO intended to acquire Units from Medline Holdings, LP for general corporate purposes. The offering includes underwriter options to purchase additional shares and details about the organizational structure, including the role of Pre-IPO Unitholders.

DRS filed

Medline Inc. is conducting its initial public offering (IPO) of Class A common stock, with shares expected to be listed on Nasdaq under the symbol 'MDLN.' The offering involves selling shares to raise capital, with proceeds used to acquire Units from Medline Holdings, LP for general corporate purposes, including debt repayment. The company has no prior public market for its stock, and the offering includes underwriter options for additional shares. The filing includes confidential treatment requests and references to risk factors, organizational structure, and use of proceeds.